Headline News about Biomarin Pharmaceuticals
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/analyst_ratings_image_3375.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/analyst_ratings_image_3297.jpeg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/analyst_ratings_image_3259.jpeg?width=720)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/price_targets_322.png?width=720)
![](https://g.foolcdn.com/editorial/images/654152/rocket.jpg)
![](https://www.investors.com/wp-content/uploads/2020/11/Stock-biomarin-03-shutt.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_2567.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_2556.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech_4.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/pill-1884777_1920_0_5_19.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_2284.png)
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template.jpg)
BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript
October 28, 2021
Via The Motley Fool
Topics
Earnings
Exposures
Financial
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/earnings_image_331.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/business_newspaper_1.png)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1784.png?width=720)
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech3_1.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/movers_image_1019.jpeg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/analyst_ratings_image_376.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1722.png)
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
September 07, 2021
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1641.png)
![](https://g.foolcdn.com/editorial/images/639120/pharmaceutical-lab-technician-examining-liquids.jpg)
![](https://images.pexels.com/photos/2280549/pexels-photo-2280549.jpeg?auto=compress&cs=tinysrgb&h=750&w=1260)
Via Talk Markets
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1242.png)
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/national-cancer-institute-xknubmnjbkg-unsplash_0.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1142.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.